Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

Overseas Regulatory Announcement

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

Set out below is the "ANNOUNCEMENT ON THE RECEIPT OF REGISTRATION APPROVAL FOR AN ADDITIONAL INDICATION OF ILAPRAZOLE SODIUM FOR INJECTION" of Livzon Pharmaceutical Group Inc.* published on the website of the Shenzhen Stock Exchange, which is set out herein for information purpose only.

The abovementioned announcement is prepared in Chinese, if there is any discrepancy between the Chinese version and the English version, the Chinese version shall prevail.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Yang Liang
Company Secretary

Zhuhai, China
7 May 2023

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

* *For identification purpose only*

LIVZON PHARMACEUTICAL GROUP INC. ANNOUNCEMENT ON THE RECEIPT OF REGISTRATION APPROVAL FOR AN ADDITIONAL INDICATION OF ILAPRAZOLE SODIUM FOR INJECTION

The Company and all members of the Board of Directors guarantee all contents of the disclosed information are true, accurate and complete, and no false representation, misleading statement or material omission is made.

Recently, Livzon Group Livzon Pharmaceutical Factory* (麗珠集團麗珠製藥廠), a wholly-owned subsidiary of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the "Company"), has received the Drug Registration Certificate (Certificate No. 2023S00625) issued by National Medical Products Administration, which has approved Ilaprazole Sodium for Injection (注射用艾普拉唑鈉) for an additional indication of "preventing stress ulcer bleeding in critically ill patients". The details are announced as follows:

I. MAIN CONTENTS OF THE REGISTRATION CERTIFICATE

Common name of the drug: Ilaprazole Sodium for Injection (注射用艾普拉唑鈉)

English name/Latin name: Ilaprazole Sodium for Injection

Trade name: Yilian (壹丽安)

Dosage Form: injection

Strength: 10mg (based on $C_{19}H_{18}N_4O_2S$)

Application: drug registration (domestic production)

Registration classification: chemical drug, category 2.4

Marketing authorization holder and manufacturer: Livzon Group Livzon Pharmaceutical Factory

Drug approval number: NMPA H20170019

Approval conclusion: Pursuant to the Pharmaceutical Administration Law of the People's Republic of China and relevant regulations, it is determined after review that the drug meets the relevant requirements for drug registration, and is therefore approved for an additional indication of "preventing stress ulcer bleeding (SUB) in critically ill patients". The drug registration certificate is hereby issued.

II. RESEARCH AND DEVELOPMENT ("R&D") OF THE DRUG AND RELEVANT INFORMATION

Ilaprazole Sodium for Injection is an innovative drug independently developed by the Company. Its original indication is for the treatment of gastrointestinal ulcer bleeding, with advantages such as long-

lasting acid suppression, minimal inter-individual variability, and low drug interactions. It is administered once a day only. The drug has now been approved for an additional indication of "preventing stress ulcer bleeding in critically ill patients", and the clinical trials for the additional indication began on 1 December 2020.

As at the date of this announcement, the accumulated direct investment in R&D expenses of the additional indication of Ilaprazole Sodium for Injection was approximately RMB42.5302 million.

III. MARKET OVERVIEW OF SIMILAR DRUGS

Currently, the proton pump inhibitors (PPIs) available in the domestic market include omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, and ilaprazole. According to IQVIA sampling statistical estimates, the sales to end customers of PPI injections in China's mainland in 2022 was approximately RMB 6,342 million.

As at the date of this announcement, the Company is the only manufacturer that has obtained the production approval for this drug in China's mainland, and no other manufacturers have applied for registration.

IV. EFFECT ON THE COMPANY AND RISK WARNING

This additional indication of Ilaprazole Sodium for Injection significantly has expanded the scope of its application, met clinical needs, and further enhanced its market competitiveness. The additional indication may be included in the Catalogue of Drugs for National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance by way of negotiations. However, the final inclusion in the medical insurance catalogue remains uncertain. The Company will strictly comply with relevant regulations and promptly fulfill its disclosure obligations based on subsequent progress. Investors are advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Livzon Pharmaceutical Group Inc. *

8 May 2023

** For identification purpose only*